Kura Oncology Email Format
Biotechnology Research
・
51-200 employees
・
San Diego, CA, USA
Kura Oncology is a clinical-stage biopharmaceutical company developing precision small-molecule therapies targeting cancer signaling pathways and genetic drivers to improve patient outcomes.
Search our verified sources for decision-makers, emails, and titles.
Start searching
VERIFIED BY CLAY
firstinitiallast@kuraoncology.com
Company Overview
Industry
Biotechnology Research
Founded
2014
Headquarters
San Diego, CA, USA
Revenue
$25M-$50M
FUNDING Stage
Public
Website
Key Executives
Troy Wilson, Ph.D., J.D. (President & Chief Executive Officer), Thomas Doyle (Senior Vice President, Finance & Accounting and Principal Accounting Officer), Kathleen Ford (Chief Operating Officer)
Tech Stack
Key Executives
4.9/5 on G2
40K+ GTM professionals
SOC 2 Type II certified
Frequently Asked Questions
What is the email format of Kura Oncology?
Kura Oncology uses the firstinitiallast format, so Jane Smith would be jsmith@kuraoncology.com.
What is KOMZIFTI, Kura Oncology's FDA-approved medicine?
KOMZIFTI (ziftomenib) is Kura Oncology's first-in-class, once-daily oral menin inhibitor approved by the FDA in November 2025 for adults with relapsed or refractory NPM1-mutated acute myeloid leukemia and included in NCCN Guidelines as a Category 2A recommended treatment.
How many employees does Kura Oncology have?
Kura Oncology has approximately 311 employees and is headquartered in San Diego, CA. You can use Clay to build a targeted list of Kura Oncology contacts and verify their email addresses before outreach.
Who leads Kura Oncology as CEO?
Troy Wilson, Ph.D., J.D. serves as President and Chief Executive Officer of Kura Oncology, with Kathleen Ford as Chief Operating Officer and Thomas Doyle as Senior Vice President of Finance and Accounting.
What cancer types is Kura Oncology's ziftomenib being studied in beyond AML in 2026?
In 2026, Kura Oncology is expanding ziftomenib into non-AML indications, including a Phase 1a/1b trial evaluating it in combination with imatinib for advanced gastrointestinal stromal tumors, alongside ongoing combination studies across NPM1-mutated and KMT2A-rearranged leukemias.
Get access to more people and company data using Clay
Leverage the power of 100+ data providers for industry-leading data coverage & quality.
4.9 rating